eMedicine from WebMD
 

eMedicine Specialties > Emergency Medicine > Toxicology

Toxicity, Calcium Channel Blocker

B Zane Horowitz, MD, FACMT, Professor, Department of Emergency Medicine, Oregon Health and Sciences University; Medical Director, Oregon Poison Center; Medical Director, Alaska Poison Control System

Updated: Oct 22, 2009

Introduction

Background

Calcium channel blockers (CCBs) were initially introduced for use in the United States in 1981. Sustained-release formulations were available 10 years later. Indications for use of these drugs are angina, hypertension, arrhythmias, and migraine prophylaxis.

Calcium channel blocker overdose is rapidly emerging as the most lethal prescription drug ingestion. Overdose by short-acting agents is characterized by rapid progression to cardiac arrest. Overdose by extended-relief formulations result in delayed onset of arrhythmias, shock, sudden cardiac collapse, and bowel ischemia.

Pathophysiology

Calcium channel blockers have the following 4 cardiovascular effects:

  1. Peripheral vasodilatation
  2. Negative chronotropy (decreased heart rate)
  3. Negative inotropy (decreased cardiac contractility)
  4. Negative dromotropy (decreased cardiac conduction)

Other physiologic responses to CCB overdose include suppression of insulin release from the pancreas and decreased free fatty acid utilization by the myocardium. These factors produce hyperglycemia, lactic acidosis, and depressed cardiac contractility.

Frequency

United States

In 1996, the American Association of Poison Control Centers (AAPCC) reported 8555 exposures to calcium channel blockers resulting in 58 fatalities and 225 major outcomes.

In 1997, the AAPCC reported 9077 exposures to calcium channel blockers, resulting in 44 fatalities and 232 major outcomes.

In 1998, the AAPCC reported 8666 exposures to calcium channel blockers, resulting in 61 fatalities and 277 major outcomes.

In 1999, the AAPCC reported 8844 exposures to calcium channel blockers, resulting in 61 fatalities and 243 major outcomes.

In 2000, the AAPCC reported 8975 exposures to calcium channel blockers, resulting in 44 fatalities and 317 major outcomes.

In 2001, the AAPCC reported 9264 exposures to calcium channel blockers, resulting in 60 fatalities and 286 major outcomes.

In 2002, the AAPCC reported 9585 exposures to calcium channel blockers, resulting in 68 fatalities and 365 major outcomes.

In 2003, the AAPCC reported 9650 exposures to calcium channel blockers, resulting in 57 fatalities and 339 major outcomes.1

In 2004, the AAPCC reported 10,513 exposures to calcium channel blockers, resulting in 62 fatalities and 356 major outcomes.

In 2006, the AAPCC reported 10,031 exposures to calcium channel blockers, resulting in 13 deaths and 316 major outcomes.

In 2007, the AAPCC reported 10,084 exposures to calcium channel blockers, resulting in 17 deaths and 74 major outcomes.2

Mortality/Morbidity

Premature discharge of patients with calcium channel blocker overdose, especially extended-release formulations, may result in severe morbidity or mortality.

  • In 1996, the AAPCC reported 58 fatalities and 225 major outcomes.
  • In 1997, the AAPCC reported 44 fatalities and 232 major outcomes.
  • In 1998, the AAPCC reported 61 fatalities and 277 major outcomes.
  • In 1999, the AAPCC reported 61 fatalities and 243 major outcomes.
  • In 2000, the AAPCC reported 44 fatalities and 317 major outcomes.
  • In 2001, the AAPCC reported 60 fatalities and 286 major outcomes.
  • In 2002, the AAPCC reported 68 fatalities and 365 major outcomes.
  • In 2003, the AAPCC reported 57 fatalities and 339 major outcomes.
  • In 2004, the AAPCC reported 62 fatalities and 356 major outcomes.
  • In 2007, the AAPCC reported 17 fatalities and 74 major outcomes.2

Age

  • In the last 10 years, there has only been a minimal decline in the percentage of pediatric exposures to CCBs of all cases called to Poison Centers nationally.
  • In 1996, with 8555 total exposures reported, 2299 exposures occurred in children younger than 6 years (27% of reported cases).
  • In 1997, with 9077 total exposures reported, 2560 exposures occurred in children younger than 6 years (28% of reported cases).
  • In 1998, with 8666 total exposures reported, 2197 exposures occurred in children younger than 6 years (25% of reported cases).
  • In 1999, with 8844 total exposures reported, 2304 exposures occurred in children younger than 6 years (26% of reported cases).
  • In 2000, with 8975 total exposures reported to calcium channel blockers, 2201 exposures occurred in children younger than 6 years (25% of reported cases).
  • In 2001, with 9264 total exposures reported to calcium channel blockers, 2249 exposures occurred in children younger than 6 years (24% of reported cases).
  • In 2002, with 9585 total exposures to calcium channel blockers, 2256 exposures occurred in children younger than 6 years (24% of reported cases).
  • In 2003, with 9650 total exposures to calcium channel blockers, 2198 exposures occurred in children younger than 6 years (23% of reported cases).
  • In 2004, with 10,513 total exposures to calcium channel blockers, 2378 exposures occurred in children younger than 6 years (23% of reported cases).
  • In 2006, with 10,031 total exposures to calcium channel blockers, 1363 exposures occurred in children younger than 6 years (16% of reported cases).
  • In 2007, with 10,084 total exposures to calcium channel blockers, 1349 exposures occurred in children younger than 6 years.2

Clinical

History

Generally, patients with calcium channel blocker overdose present with empty pill bottles or a witnessed ingestion. When a history is unavailable, patients present with a cardiodepressive toxidrome and decreased heart rate and blood pressure.

  • Children can become symptomatic with as little as one tablet. In young children, calcium channel blockers have the potential to be fatal with single tablet ingestions. Delayed onset of hypotension has been reported in children with extended-release tablet ingestion. All children with suspected calcium channel blocker ingestions of any amount should be evaluated in a health care facility and monitored in an ICU setting for signs of delayed toxicity.
  • Carefully question the caretakers of children who present with depressed blood pressure or heart rate to see if anyone in the household is taking blood pressure or heart medicine.
  • In adults, deliberate overdoses are more likely to involve multiple medications, and alcohol is frequently a co-ingestant.
  • Establishing the complete list of medications that the patient may have had access to is important.
  • AAPCC consensus panel recommends the following ingestion amounts be sent into a hospital for evaluation (co-ingestants must be taken into account, these amounts assume an isolated accidentalingestion of only the calcium blocking medication):1
DrugAdult DosagePediatric Dosage
Amlodipine>10 mg>0.3 mg/kg
Bepridil>300 mgAny amount
Diltiazem>120 mg immediate release, >360 mg sustained release>1 mg/kg
Felodipine>10 mg>0.3 mg/kg
Isradipine>20 mg>0.1 mg/kg
Nicardipine>40 mg immediate release, >60 mg sustained release>1.25 mg/kg
Nifedipine>30 mg immediate release, >120 sustained releaseAny amount
Nimodipine>60 mgAny amount
Nisoldipine>30 mg

Any amount

Verapamil>120 mg immediate release, >480 mg sustained release>2.5 mg/kg

Physical

Focus the physical examination on mental status and cardiovascular assessment.

  • Hypotension
  • Bradycardia, with variable degrees of heart block
  • Altered mental status or seizures secondary to hypotension
  • Occasional cases of bowel infarction caused by mesenteric underperfusion

Causes

  • Verapamil3,4,5 (eg, Calan, Isoptin), a phenylalkylamine, produces hypotension and heart block.
    • Several extended-release formulations are available (eg, Isoptin SR, Calan SR, Verelan, Covera-HS).
    • All extended-release formulations require longer observation periods to ensure that no delayed onset of toxicity occurs.
  • Nifedipine (eg, Procardia, Procardia XL, Adalat, Adalat CC) is representative of the dihydropyridine class, which produces profound hypotension with less heart block.
    • Overdoses with CCBs in this class may present with reflex tachycardia.
    • Other drugs in the dihydropyridine class of calcium channel blockers act similarly; they include nicardipine (eg, Cardene, Carden SR), nimodipine (Nimotop), nitrendipine, isradipine (DynaCirc, DynaCirc SR), amlodipine (Norvasc),6,7 felodipine (Plendil), and nisoldipine (Sular).
    • Amlodipine has a particularly long half-life of 45 hours.
    • All dihydropyridines exert their greatest effect on vascular smooth muscle, producing vasodilatation.
    • The sustained-release or controlled-release preparations also need prolonged observation for the same reasons prolonged observation is required for extended-release formulations.
  • Diltiazem (Cardizem), the only CCB in the benzothiazepine class, produces significant antidromotropic effects.
    • Patients ingesting diltiazem typically present with heart block and lesser degrees of hypotension.
    • Delayed-release formulations include Cardizem CD, Cardizem SR, Dilacor XR, Tiamate, Teczem, and Tiazac. These require longer observation periods to insure no delayed onset of toxicity.
  • Bepridil (Vascor), used for refractory angina, is a unique calcium channel blocker with some sodium channel blocking activity.
    • Bepridil has been shown to prolong the QTc interval through its potassium channel blocking effect; therefore, it may cause torsade de pointes.
    • About 1% of patients treated with this drug experienced ventricular arrhythmias.
  • Mibefradil (Posicor), was a novel selective T-channel calcium channel blocker, which was alleged to have less negative inotropy at therapeutic concentrations; however, it has been removed from the worldwide market after multiple adverse drug interactions were reported.
    • Mibefradil is proarrhythmic and may increase levels of tricyclic antidepressants and many other medications through competitive inhibition of cytochrome P450 C4A.
    • When patients are taking mibefradil, drugs that prolong the QTc interval (eg, terfenadine) should be used cautiously or not at all.
    • Soon after mibefradil's release, a box warning was added to the package insert; it warned that AV block and bradycardia has occurred with standard use, especially if the drug is taken in conjunction with beta-blockers or other calcium channel blockers.
    • On June 8, 1998, the drug was withdrawn from the US market because of adverse drug interactions with 26 other medications. A report by Mullins et al detailed 4 life-threatening cases of cardiogenic shock when mibefradil was used at recommended doses with calcium channel blockers and beta-blockers.8

Differential Diagnoses

Lactic Acidosis
Toxicity, Antidysrhythmic
Myocardial Infarction
Toxicity, Beta-blocker
Plant Poisoning, Glycosides - Coumarin
Toxicity, Clonidine
Shock, Cardiogenic
Toxicity, Digitalis
Toxicity, Antidepressant

Other Problems to Be Considered

The most likely differential diagnostic problems for a cardiodepressive toxic syndrome are as follows:

Calcium channel blocker overdose
Beta-blocker overdose
Digitalis overdose
Clonidine overdose
Acute myocardial infarction with cardiogenic shock

Workup

Laboratory Studies

  • Hyperglycemia may occur as calcium channel blockade inhibits insulin release.
  • Lactic acidosis may occur and an arterial blood gas (ABG) may suggest acidemia.
  • Blood levels are generally not available with any reasonable turn around time. Treatment must be instituted based on symptoms. Blood levels are available to confirm elevated levels if the diagnosis is in doubt.

Imaging Studies

  • A chest x-ray may be helpful to determine heart size and presence or absence of congestive heart failure. In patients with CHF, aggressive fluid boluses to treat hypotension may exacerbate heart failure or cause acute pulmonary edema.
  • If bowel obstruction is suspected, abdominal radiography is recommended. Color flow vascular ultrasonography of the intra-abdominal arterial supply may confirm bowel infarction.

Other Tests

  • Obtain a 12-lead electrocardiogram (ECG) for all cases and perform continuous cardiac monitoring until stable.
  • Cardiac biomarkers, such as troponin I, may help differentiate drug-induced bradycardia from ischemic causes.

Procedures

  • Transcutaneous or transvenous pacing may be required if hemodynamically unstable heart block fails to respond to medical therapy.

Treatment

Prehospital Care

Rapid transport before the patient deteriorates is crucial. Empiric use of glucagon (adults: 5-15 mg IV) may be warranted for patients with an unknown overdose presenting with bradycardia or hypotension. Consider using calcium only if a witness confirms a calcium channel blocker overdose; calcium may induce fatal arrhythmias in digoxin overdose, which can present with similar findings. Treat hypotension with fluid boluses. If profound hypotension fails to respond to fluid resuscitation, administer a dopamine or norepinephrine drip, if permitted by local protocol. If the patient deteriorates to cardiac arrest from a calcium channel blocker overdose, perform prolonged cardiopulmonary resuscitation (CPR) in the field because patients have survived neurologically intact after an hour of CPR.

  • Establish ABCs, obtain IV access, provide oxygen, and monitor closely.
  • Avoid ipecac syrup.1
  • Administer IV glucagon if hypotension is present.1 Administer fluid bolus of normal saline if no evidence of decompensated congestive heart failure exists.
  • Atropine may be tried if hemodynamically significant bradycardia occurs; however, heart block is usually resistant to atropine in calcium channel blocker toxicity. Mid-dose dopamine (5-10 mcg/kg/min) may improve heart rate and contractility.
  • Administer IV calcium chloride (up to 4 g) and/or glucagon (up to 15 mg) if hypotension persists.1
  • Consider dopamine or norepinephrine infusion if a long transport time is likely, as permitted by local prehospital care protocols.

Emergency Department Care

Aggressive cardiovascular support is necessary for managing the massive calcium channel blocker overdose. While calcium chloride in high doses (4-6 g) may overcome some of the adverse effects of CCBs, it rarely restores normal cardiovascular status. According to many case reports, glucagon and inamrinone (formerly amrinone) have been used with good results. However, vasopressors are frequently necessary for adequate resuscitation and should be started early if hypotension occurs (see Medication). Additional basic overdose management includes airway protection, gastric lavage, and activated charcoal.

  • Gastric decontamination9
    • Gastric lavage may be useful in early presentations (<1-2 h postingestion), especially in cases of extended- or delayed-release tablet ingestion.
    • Activated charcoal (50-100 g PO) should be administered after gastric lavage.
    • Completely asymptomatic patients may be treated with activated charcoal and close observation.
    • Whole bowel irrigation with polyethylene glycol solution (eg, GoLYTELY, NuLytely, Colyte) may be useful in extended-release preparations. However, be sure that ileus, bowel obstruction, and bowel ischemia have not occurred; case reports of bowel ischemia and infarction have appeared with calcium channel blocker overdose.
  • Medications
    • Administer glucagon (5-15 mg IV bolus) followed by an infusion after fluid resuscitation is performed for persistent hypotension. Recommended infusion rate for adults is 10-15 mg/h. Recommended pediatric dose is 50 mcg/kg IV over 5 minutes, followed by an infusion at 0.07 mg/kg/h.
    • Calcium chloride10 (1-4 g IV, slowly) can be administered for hypotension or heart block.
    • Thirty milliliters of 10% calcium gluconate can be administered over 10-15 minutes. Boluses may be repeated every 15-20 minutes for a total of 3 doses. After the third bolus, the ionized calcium level should be checked. Recommended pediatric dose of calcium gluconate is 60 mg/kg, with a maximum dose of 1 g.
    • Vasopressor support to maintain blood pressure and cardiac output is critical. In the hypotensive patient, administer dopamine at medium-to-high doses early for cardiac contractility for heart rate support and norepinephrine for blood pressure support. Inamrinone may be of additional benefit in profound cardiac contractile failure (see Medication).
    • In a series of case reports, high-dose insulin infusion (0.1-1 U/kg/h) with dextrose infusion (usually D10W-D25W) to maintain normal serum glucose levels have been successful for stabilizing cardiac output.9,11,12 When using this technique, frequent monitoring of glucose and potassium every 20-30 minutes is necessary.
  • Anecdotal efficacy of cardiopulmonary bypass exists in cases of severe poisoning resistant to aggressive medical treatments, such as patients failing glucagon and norepinephrine infusions.
  • A patient developing acute respiratory distress syndrome (ARDS) has been successfully treated with partial liquid ventilation; however, this procedure is no longer available.

Consultations

  • Consult an AAPCC certified regional poison control center or a medical toxicologist in all cases to assist in management because several options for treatment exist and each case is unique.

Medication

Aggressive cardiovascular support is necessary for management of massive calcium channel blocker overdose. While calcium may overcome some adverse effects of CCBs, it rarely restores normal cardiovascular status. According to many case reports, glucagon and inamrinone (formerly inamrinone) have been used with good results. However, vasopressors are frequently necessary for adequate resuscitation and should be started early if hypotension occurs. Recent case reports suggest that use of high dose insulin, with maintenance of euglycemia by dextrose infusion, may be efficacious.

GI decontaminants

Used to minimize systemic absorption of ingested calcium channel blockers.


Activated charcoal (Liqui-Char)

Most useful within 4 h of ingestion, repeated doses may be used, especially with ingestions of sustained-released agents.

Dosing

Adult

1 g/kg PO (first dose usually with cathartic), up to 50-100 g; may repeat dose q4h at 0.5 g/kg (alternate with cathartic, monitor for active bowel sounds)

Pediatric

1 g/kg PO (<2 y: omit cathartic), up to 15-30 g; may repeat dose q4h at 0.5 g/kg (alternate with cathartic, monitor for active bowel sounds)

Interactions

Effectiveness of other PO medications may decrease with coadministration

Contraindications

Documented hypersensitivity; poisoning or overdose of mineral acids and alkalies; unprotected airway with absent gag reflex

Precautions

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Monitor for active bowel sounds before readministration to minimize risk of charcoal ileus; not very effective in poisonings of ethanol, methanol, and iron salts; can administer after gastric lavage; gastric lavage returns are black

Antidotes

Used to reverse calcium channel blockade or counteract the effects of reduced intracellular calcium.

Some animal models and human case reports suggest a significant response in cardiac output with hyperinsulinemic therapy with concomitant maintenance of euglycemia with supplemental dextrose. No prospective human trials exist to verify this result.


Calcium chloride

Moderates nerve and muscle-performance by regulating action potential excitation threshold. Used to overcome calcium channel blockade.

Dosing

Adult

1000-4000 mg (1-4 g) slow IV push of 10% solution

Pediatric

20-25 mg/kg IV push (0.2 mL/kg of 10% solution, repeat if response occurs)

Interactions

Coadministration with digoxin may cause arrhythmias; coadministration with thiazides may induce hypercalcemia; may antagonize effects of calcium channel blockers, atenolol, and sodium polystyrene sulfonate; when used intravenously precipitates with sodium bicarbonate and may be sclerosing to peripheral veins

Contraindications

Ventricular fibrillation not associated with hyperkalemia; digitalis toxicity; hypercalcemia; renal insufficiency; cardiac disease

Precautions

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Administer slowly (not to exceed 0.5-1 mL/min) to avoid extravasation; hypercalcemia may occur in renal failure; check ionized calcium levels after 2-4 boluses and q4-6h during calcium infusion


Glucagon

Acts via cAMP to increase cardiac contractility and also may decrease heart block. One study suggests that glucagon has maximal effect in normocalcemic environment. Hypocalcemia and hypercalcemia decrease efficacy; therefore, consider IV glucagon before calcium.
Mix in a Mini-Bag (50-100 mL) of NS and infuse over several minutes.
Do not use diluent (eg, propylene glycol) supplied with single use kits.

Dosing

Adult

5-15 mg IV

Pediatric

150 mcg/kg IV over 1 min followed by 2-5 mg/h infusion

Interactions

May enhance effects of anticoagulants (although onset may be delayed); monitor prothrombin activity and for signs of bleeding in patients receiving anticoagulants; adjust dose accordingly; do not use diluent when administering high doses of glucagon

Contraindications

Documented hypersensitivity; pheochromocytoma

Precautions

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Vomiting is common and may be related to rate of infusion; thus, should be given slowly over 5-10 min; monitor blood glucose levels in hypoglycemic patients until asymptomatic; effective in treating hypoglycemia only if sufficient liver glycogen is present; because liver glycogen availability is necessary to treat hypoglycemic patients, has virtually no effects on patients with starvation, adrenal insufficiency, or chronic hypoglycemia; protect the airway or pretreat with antiemetics because vomiting frequently occurs


Inamrinone - formerly amrinone (Inocor)

Phosphodiesterase inhibitor that acts by inhibiting breakdown of cAMP, thus prolonging effect on the release of calcium into the cytosol. Increases cardiac contractility outside the alpha- and beta-adrenergic system through nonspecific stimulation of cAMP. Although milrinone and inamrinone are available, experience in treating CCB overdoses is limited to inamrinone.
Use with severely depressed cardiac output.

Dosing

Adult

0.75 mg/kg IV initial, followed by 5-10 mcg/kg/min maintenance infusion; additionally, 0.75 mg/kg may be administered 30 min after therapy begins; not to exceed 10 mg/kg/d

Pediatric

Not established
Suggested dosing: Administer as in adults; infants may require larger doses

Interactions

Coadministration with diuretics may result in hypovolemia and decrease in filling pressure; cardiac glycosides have additive effects on inamrinone; admixing with furosemide or dextrose may cause precipitation

Contraindications

Documented hypersensitivity; uncorrected hypovolemia

Precautions

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Discontinue therapy if symptoms of liver toxicity develop; correct hypokalemic states before therapy; hypotension may occur during bolus


Insulin (Novolin, Humulin)

CCBs may inhibit pancreatic insulin release and block free fatty acid uptake and utilization by the myocardium, which is needed for myocardial work and contractility. High dose insulin may change myocardial energy consumption from free fatty acids to carbohydrates.
Administer dextrose through a central line as D25 or D50, with mean doses of 20 g/h reported with frequent (at least hourly) monitoring of serum glucose.

Dosing

Adult

0.1-1 Units/kg/h IV, with mean doses of 0.5 Units/kg/h

Pediatric

Not established

Interactions

Medications that may decrease hypoglycemic effects include acetazolamide, AIDS antivirals, asparaginase, phenytoin, nicotine isoniazid, diltiazem, diuretics, corticosteroids, thiazide diuretics, thyroid estrogens, ethacrynic acid, calcitonin, oral contraceptives, diazoxide, dobutamine phenothiazines, cyclophosphamide, dextrothyroxine, lithium carbonate, epinephrine, morphine sulfate, and niacin; medications that may increase hypoglycemic effects include calcium, ACE inhibitors, alcohol, tetracyclines, beta-blockers, lithium carbonate, anabolic steroids, pyridoxine, salicylates, MAOIs, mebendazole, sulfonamides, phenylbutazone, chloroquine, clofibrate, fenfluramine, guanethidine, octreotide, pentamidine, and sulfinpyrazone

Contraindications

Documented hypersensitivity; hypoglycemia

Precautions

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Hyperthyroidism may increase renal clearance, and more may be required to treat hyperkalemia; hypothyroidism may delay turnover, and less may be required to treat hyperkalemia; monitor glucose carefully; dose adjustments of insulin may be necessary in patients with renal and hepatic dysfunction

Cardiovascular agents

Vasopressors augment blood pressure by alpha stimulation induced vasoconstriction.

Atropine rarely helps significant bradycardia or heart block; isoproterenol has an adverse cardiovascular hemodynamic profile greatly diminishing its potential for use in bradycardia. Use these agents only after considering the above factors.


Norepinephrine (Levophed)

Stimulates beta 1- and alpha-adrenergic receptors, which, in turn, increases cardiac muscle contractility and heart rate as well as vasoconstriction. As a result, systemic blood pressure and coronary blood-flow increases.

Dosing

Adult

2 mcg/min IV; titrate to effect

Pediatric

0.1 mcg/kg/min IV; titrate to effect

Interactions

Enhance the pressor response by blocking the reflex bradycardia caused by norepinephrine

Contraindications

Documented hypersensitivity; peripheral or mesenteric vascular thrombosis because ischemia may be increased and the area of the infarct extended

Precautions

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Correct blood-volume depletion, if possible, before therapy; administer into a large vein because extravasation may cause severe tissue necrosis; caution in occlusive vascular disease


Epinephrine (Adrenalin)

Has alpha-agonist effects that include increased peripheral vascular resistance, reversed peripheral vasodilatation, systemic hypotension, and vascular permeability. Beta-agonist effects include bronchodilatation, chronotropic cardiac activity, and positive inotropic effects.

Dosing

Adult

2 mcg/min IV; titrate to effect

Pediatric

0.1 mcg/min IV; titrate to effect

Interactions

Increases toxicity of beta- and alpha-adrenergic blocking agents and that of halogenated inhalational anesthetics

Contraindications

Documented hypersensitivity; cardiac arrhythmias; angle-closure glaucoma; local anesthesia in areas such as fingers or toes because vasoconstriction may produce sloughing of tissue; do not use during labor (may delay second stage)

Precautions

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Caution in elderly persons, prostatic hypertrophy, hypertension, cardiovascular disease, diabetes mellitus, hyperthyroidism, and cerebrovascular insufficiency; rapid IV infusions may cause fatality from cerebrovascular hemorrhage or cardiac arrhythmias; monitor IV site for signs of extravasation, which can cause local tissue necrosis (if extravasation occurs, local infiltration of phentolamine may prevent tissue necrosis)


Atropine (Atropair)

Used to increase heart rate through vagolytic effects, causing an increase in cardiac output. Seldom produces an adequate response.

Dosing

Adult

Hypotension: 0.5-1 mg IV with repeated doses at 5 min intervals until desired response
Cardiac arrest: 1 mg IV repeated q3-5min
Minimal dose: 0.5 mg IV
Maximal dose: 0.04 mg/kg or 3 mg IV is fully vagolytic

Pediatric

Hypotension: 0.02 mg/kg IV; minimum dose: 0.1 mg IV
Cardiac arrest: Maximum single dose is 0.5 mg in children and 1 mg in adolescents; may repeat above dose once, not to exceed 1 mg in children and 2 mg in adolescents

Interactions

Coadministration with other anticholinergics has additive effects; pharmacologic effects of atenolol and digoxin may increase; antipsychotic effects of phenothiazines may decrease; tricyclic antidepressants with anticholinergic activity may increase effects

Contraindications

Documented hypersensitivity; thyrotoxicosis; narrow-angle glaucoma; tachycardia

Precautions

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Avoid in Down syndrome and/or children with brain damage to prevent hyperreactive response; avoid in coronary heart disease, congestive heart failure, cardiac arrhythmias, and hypertension; caution in peritonitis, ulcerative colitis, hepatic disease, and hiatal hernia with reflux esophagitis; in prostatic hypertrophy, prostatism can have dysuria and may require catheterization; administration in doses of <0.5 mg can produce paradoxical bradycardia


Isoproterenol (Isuprel)

Has beta 1- and beta 2-adrenergic receptor activity. Binds beta- adrenergic receptors of heart, smooth muscle of bronchi, skeletal muscle, vasculature, and alimentary tract. Has positive inotropic and chronotropic actions. May be used if transvenous or transcutaneous pacemaker is unavailable or not capturing. Dopamine should be tried first for rate control because isoproterenol has several adverse cardiovascular effects. Can cause increased myocardial workload and precipitate ischemia. Vasodilatory properties may worsen hypotension. Avoid use unless all other options have failed.

Dosing

Adult

2-4 mcg/min IV; titrate cautiously

Pediatric

0.1 mcg/kg/min IV; titrate cautiously

Interactions

Tricyclic antidepressants may potentiate pressor response of direct-acting vasopressors; slowly inactivated at alkaline pH

Contraindications

Documented hypersensitivity; tachyarrhythmias; tachycardia or heart block caused by digitalis intoxication; ventricular arrhythmias which require inotropic therapy; angina pectoris

Precautions

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

By increasing myocardial oxygen requirements while decreasing effective coronary perfusion, may have a deleterious effect on the injured or failing heart; in some patients, presumably with organic disease of the AV node and its branches, may paradoxically worsen heart blocks or precipitate Adams-Stokes attacks; caution in coronary artery disease, coronary insufficiency, diabetes or hyperthyroidism and sensitivity to sympathomimetic amines; if heart rate exceeds 110 BPM, may be advisable to decrease infusion rate or temporarily discontinue infusion

Follow-up

Further Inpatient Care

  • Admit all ingestions to ICU monitoring for 6-12 hours in standard-release preparation overdose and for 24-36 hours in extended-release or once-a-day preparation overdose.

Further Outpatient Care

  • If patient is hemodynamically stable, observation may occur in observation units if available to the ED.
    • Adequate ICU capabilities must be present in the observation unit because these patients may require intubation, pacemaker placement, or vasopressor support.
    • Only asymptomatic ingestions should be watched in an observation unit, and if cardiodepressive symptoms occur, transfer the patient to an ICU setting.
  • After adequate observation time, the asymptomatic patient may be referred for psychiatric evaluation.

Transfer

  • Patients must be completely asymptomatic to be transferred and should only be transferred with units capable of advanced cardiac life support (ACLS), including intubation and pacing.

Complications

  • Anoxic encephalopathy from prolonged CNS hypoxia
  • Bowel infarction from underperfusion of mesenteric circulation
  • Adult respiratory distress syndrome

Prognosis

  • The patient has a reasonable prognosis if treated aggressively, as long as they do not deteriorate to cardiogenic shock.
    • However, even with deterioration, prolonged attempts at resuscitation of the toxin-induced cardiac arrest are warranted.
    • Anecdotal cases of prolonged CPR with aggressive vasopressor support have yielded neurologically intact survivors.

Patient Education

  • Advise older patients to keep all medications away from children and to use child-resistant caps if children live in or visit their home.
  • Educate grandparents who keep pills in easy-to-open pill-tenders of the risks to their grandchildren, who can easily open these types of containers.
  • Advise adults to keep the number of the nearest poison control center near the phone and to call them even for a single tablet ingestion by children.
  • For excellent patient education resources, visit eMedicine's Drug Overdose Center and Poisoning - First Aid and Emergency Center. Also, see eMedicine's patient education articles Poisoning, Drug Overdose, Activated Charcoal, and Poison Proofing Your Home.

Miscellaneous

Medicolegal Pitfalls

  • Extended-release tablets have a delayed onset of up to 12 hours. Releasing a patient who has ingested an extended-release tablet too soon places them in jeopardy.

Special Concerns

  • Bepridil is a unique calcium channel blocker with antiarrhythmic activity. It is also proarrhythmic, even at therapeutic doses, and may cause torsade de pointes.
  • Mibefradil, which has been taken off the market, has been associated with profound cardiogenic shock and fatality when switching to another CCB after stopping mibefradil.

References

  1. [Guideline] Olson KR, Erdman AR, Woolf AD, et al. Calcium channel blocker ingestion: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila). 2005;43(7):797-822. [Medline].

  2. Bronstein AC, Spyker DA, Cantilena LR Jr, Green JL, Rumack BH, Heard SE. 2007 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 25th Annual Report. Clin Toxicol (Phila). Dec 2008;46(10):927-1057. [Medline].

  3. Sim MT, Stevenson FT. A fatal case of iatrogenic hypercalcemia after calcium channel blocker overdose. J Med Toxicol. Mar 2008;4(1):25-9. [Medline].

  4. Kolcz J, Pietrzyk J, Januszewska K, Procelewska M, Mroczek T, Malec E. Extracorporeal life support in severe propranolol and verapamil intoxication. J Intensive Care Med. Nov-Dec 2007;22(6):381-5. [Medline].

  5. Batalis NI, Harley RA, Schandl CA. Verapamil toxicity: an unusual case report and review of the literature. Am J Forensic Med Pathol. Jun 2007;28(2):137-40. [Medline].

  6. Smith SW, Ferguson KL, Hoffman RS, Nelson LS, Greller HA. Prolonged severe hypotension following combined amlodipine and valsartan ingestion. Clin Toxicol (Phila). Jun 2008;46(5):470-4. [Medline].

  7. Blankfield RP, Iftikhar I, Glickman E, Harris S. Temperature and blood pressure following amlodipine overdose. Wilderness Environ Med. Spring 2008;19(1):39-41. [Medline].

  8. Mullins ME, Horowitz BZ, Linden DH, Smith GW, Norton RL, Stump J. Life-threatening interaction of mibefradil and beta-blockers with dihydropyridine calcium channel blockers. JAMA. Jul 8 1998;280(2):157-8. [Medline].

  9. Patel NP, Pugh ME, Goldberg S, Eiger G. Hyperinsulinemic euglycemia therapy for verapamil poisoning: a review. Am J Crit Care. Sep 2007;16(5):498-503. [Medline].

  10. Hung YM, Olson KR. Acute amlodipine overdose treated by high dose intravenous calcium in a patient with severe renal insufficiency. Clin Toxicol (Phila). 2007;45(3):301-3. [Medline].

  11. Patel NP, Pugh ME, Goldberg S, Eiger G. Hyperinsulinemic euglycemia therapy for verapamil poisoning: case report. Am J Crit Care. Sep 2007;16(5):520, 518-9. [Medline].

  12. Greene SL, Gawarammana I, Wood DM, Jones AL, Dargan PI. Relative safety of hyperinsulinaemia/euglycaemia therapy in the management of calcium channel blocker overdose: a prospective observational study. Intensive Care Med. Nov 2007;33(11):2019-24. [Medline].

  13. Abascal VM, Larson MG, Evans JC, Blohm AT, Poli K, Levy D. Calcium antagonists and mortality risk in men and women with hypertension in the Framingham Heart Study. Arch Intern Med. Sep 28 1998;158(17):1882-6. [Medline].

  14. Ashraf M, Chaudhary K, Nelson J, Thompson W. Massive overdose of sustained-release verapamil: a case report and review of literature. Am J Med Sci. Dec 1995;310(6):258-63. [Medline].

  15. Barrow PM, Houston PL, Wong DT. Overdose of sustained-release verapamil. Br J Anaesth. Mar 1994;72(3):361-5. [Medline].

  16. Belson MG, Gorman SE, Sullivan K, Geller RJ. Calcium channel blocker ingestions in children. Am J Emerg Med. Sep 2000;18(5):581-6. [Medline].

  17. Billups SJ, Carter BL. Mibefradil: a new class of calcium-channel antagonists. Ann Pharmacother. Jun 1998;32(6):659-71. [Medline].

  18. Boden WE, Korr KS, Bough EW. Nifedipine-induced hypotension and myocardial ischemia in refractory angina pectoris. JAMA. Feb 22 1985;253(8):1131-5. [Medline].

  19. Brass BJ, Winchester-Penny S, Lipper BL. Massive verapamil overdose complicated by noncardiogenic pulmonary edema. Am J Emerg Med. Sep 1996;14(5):459-61. [Medline].

  20. Brayer AF, Wax P. Accidental ingestion of sustained release calcium channel blockers in children. Vet Hum Toxicol. Apr 1998;40(2):104-6. [Medline].

  21. Buckley N, Dawson AH, Howarth D, Whyte IM. Slow-release verapamil poisoning. Use of polyethylene glycol whole-bowel lavage and high-dose calcium. Med J Aust. Feb 1 1993;158(3):202-4. [Medline].

  22. Chernow B, Zaloga GP, Malcolm D, Willey SC, Clapper M, Holaday JW. Glucagon's chronotropic action is calcium dependent. J Pharmacol Exp Ther. Jun 1987;241(3):833-7. [Medline].

  23. Connolly DL, Nettleton MA, Bastow MD. Massive diltiazem overdose. Am J Cardiol. Sep 15 1993;72(9):742-3. [Medline].

  24. Derlet RW, Horowitz BZ. Cardiotoxic drugs. Emerg Med Clin North Am. Nov 1995;13(4):771-91. [Medline].

  25. Doyon S, Roberts JR. The use of glucagon in a case of calcium channel blocker overdose. Ann Emerg Med. Jul 1993;22(7):1229-33. [Medline].

  26. Fant JS, James LP, Fiser RT, Kearns GL. The use of glucagon in nifedipine poisoning complicated by clonidine ingestion. Pediatr Emerg Care. Dec 1997;13(6):417-9. [Medline].

  27. Fauville JP, Hantson P, Honore P, Belpaire F, Rosseel MT, Mahieu P. Severe diltiazem poisoning with intestinal pseudo-obstruction: case report and toxicological data. J Toxicol Clin Toxicol. 1995;33(3):273-7. [Medline].

  28. Gutierrez H, Jorgensen M. Colonic ischemia after verapamil overdose. Ann Intern Med. Mar 1 1996;124(5):535. [Medline].

  29. Haddad LM. Resuscitation after nifedipine overdose exclusively with intravenous calcium chloride. Am J Emerg Med. Oct 1996;14(6):602-3. [Medline].

  30. Hendren WG, Schieber RS, Garrettson LK. Extracorporeal bypass for the treatment of verapamil poisoning. Ann Emerg Med. Sep 1989;18(9):984-7. [Medline].

  31. Herrington DM, Insley BM, Weinmann GG. Nifedipine overdose. Am J Med. Aug 1986;81(2):344-6. [Medline].

  32. Hofer CA, Smith JK, Tenholder MF. Verapamil intoxication: a literature review of overdoses and discussion of therapeutic options. Am J Med. Oct 1993;95(4):431-8. [Medline].

  33. Horowitz BZ, Rhee KJ. Massive verapamil ingestion: a report of two cases and a review of the literature. Am J Emerg Med. Nov 1989;7(6):624-31. [Medline].

  34. Howarth DM, Dawson AH, Smith AJ, Buckley N, Whyte IM. Calcium channel blocking drug overdose: an Australian series. Hum Exp Toxicol. Mar 1994;13(3):161-6. [Medline].

  35. Ioulios P, Charalampos M, Efrossini T. The spectrum of cutaneous reactions associated with calcium antagonists: a review of the literature and the possible etiopathogenic mechanisms. Dermatol Online J. Dec 2003;9(5):6. [Medline].

  36. Kanagarajan K, Marraffa JM, Bouchard NC, Krishnan P, Hoffman RS, Stork CM. The use of vasopressin in the setting of recalcitrant hypotension due to calcium channel blocker overdose. Clin Toxicol (Phila). 2007;45(1):56-9. [Medline].

  37. Katz AM. Calcium channel diversity in the cardiovascular system. J Am Coll Cardiol. Aug 1996;28(2):522-9. [Medline].

  38. Kerns W 2nd. Management of beta-adrenergic blocker and calcium channel antagonist toxicity. Emerg Med Clin North Am. May 2007;25(2):309-31; abstract viii. [Medline].

  39. Kline JA, Leonova E, Raymond RM. Beneficial myocardial metabolic effects of insulin during verapamil toxicity in the anesthetized canine. Crit Care Med. Jul 1995;23(7):1251-63. [Medline].

  40. Kline JA, Tomaszewski CA, Schroeder JD, Raymond RM. Insulin is a superior antidote for cardiovascular toxicity induced by verapamil in the anesthetized canine. J Pharmacol Exp Ther. Nov 1993;267(2):744-50. [Medline].

  41. Koch AR, Vogelaers DP, Decruyenaere JM, Callens B, Verstraete A, Buylaert WA. Fatal intoxication with amlodipine. J Toxicol Clin Toxicol. 1995;33(3):253-6. [Medline].

  42. Koury SI, Stone CK, Thomas SH. Amrinone as an antidote in experimental verapamil overdose. Acad Emerg Med. Aug 1996;3(8):762-7. [Medline].

  43. Lacinová L. Pharmacology of recombinant low-voltage activated calcium channels. Curr Drug Targets CNS Neurol Disord. Apr 2004;3(2):105-11. [Medline].

  44. Leesar MA, Martyn R, Talley JD, Frumin H. Noncardiogenic pulmonary edema complicating massive verapamil overdose. Chest. Feb 1994;105(2):606-7. [Medline].

  45. Levine M, Boyer EW, Pozner CN, et al. Assessment of hyperglycemia after calcium channel blocker overdoses involving diltiazem or verapamil. Crit Care Med. Sep 2007;35(9):2071-5. [Medline].

  46. Lip GY, Ferner RE. Overdose of diltiazem. BMJ. Jul 16 1994;309(6948):193. [Medline].

  47. Lip GY, Ferner RE. Poisoning with anti-hypertensive drugs: calcium antagonists. J Hum Hypertens. Mar 1995;9(3):155-61. [Medline].

  48. Luomanmaki K, Tiula E, Kivisto KT, Neuvonen PJ. Pharmacokinetics of diltiazem in massive overdose. Ther Drug Monit. Apr 1997;19(2):240-2. [Medline].

  49. Mahr NC, Valdes A, Lamas G. Use of glucagon for acute intravenous diltiazem toxicity. Am J Cardiol. Jun 1 1997;79(11):1570-1. [Medline].

  50. Malcolm N, Callegari P, Goldberg J, et al. Massive diltiazem overdosage: clinical and pharmacokinetic observations. Drug Intell Clin Pharm. Nov 1986;20(11):888. [Medline].

  51. Miller MA, Masneri DA, Herold T. Delayed clinical decompensation and death after pediatric nifedipine overdose. Am J Emerg Med. Feb 2007;25(2):197-8. [Medline].

  52. Mycyk MB, Bryant SM. Is simple bedside glucose assessment prognostic in calcium channel blocker overdose?. Crit Care Med. Sep 2007;35(9):2216-7. [Medline].

  53. Osterhoudt KC, Henretig. How much confidence that calcium channel blockers are safe?. Vet Human Toxicol. 1998;40:239.

  54. Pearigen PD, Benowitz NL. Poisoning due to calcium antagonists. Experience with verapamil, diltiazem and nifedipine. Drug Saf. Nov-Dec 1991;6(6):408-30. [Medline].

  55. Plewa MC, Martin TG, Menegazzi JJ, Seaberg DC, Wolfson AB. Hemodynamic effects of 3,4-diaminopyridine in a swine model of verapamil toxicity. Ann Emerg Med. Mar 1994;23(3):499-507. [Medline].

  56. Proano L, Chiang WK, Wang RY. Calcium channel blocker overdose. Am J Emerg Med. Jul 1995;13(4):444-50. [Medline].

  57. Quezado Z, Lippmann M, Wertheimer J. Severe cardiac, respiratory, and metabolic complications of massive verapamil overdose. Crit Care Med. Mar 1991;19(3):436-8. [Medline].

  58. Ramoska EA, Spiller HA, Myers A. Calcium channel blocker toxicity. Ann Emerg Med. Jun 1990;19(6):649-53. [Medline].

  59. Ramoska EA, Spiller HA, Winter M, Borys D. A one-year evaluation of calcium channel blocker overdoses: toxicity and treatment. Ann Emerg Med. Feb 1993;22(2):196-200. [Medline].

  60. Ranniger C, Roche C. Are one or two dangerous? Calcium channel blocker exposure in toddlers. J Emerg Med. Aug 2007;33(2):145-54. [Medline].

  61. Roberts D, Honcharik N, Sitar DS, Tenenbein M. Diltiazem overdose: pharmacokinetics of diltiazem and its metabolites and effect of multiple dose charcoal therapy. J Toxicol Clin Toxicol. 1991;29(1):45-52. [Medline].

  62. Rogers R, Prpic R. Profound symptomatic bradycardia associated with combined mibefradil and beta-blocker therapy. Med J Aust. Oct 19 1998;169(8):425-7. [Medline].

  63. Roper TA, Sykes R, Gray C. Fatal diltiazem overdose: report of four cases and review of the literature. Postgrad Med J. Jun 1993;69(812):474-6. [Medline].

  64. Shah AR, Passalacqua BR. Case report: sustained-release verapamil overdose causing stroke: an unusual complication. Am J Med Sci. Dec 1992;304(6):357-9. [Medline].

  65. Smilkstein MJ. Perfusion salad: making sense of verapamil overdose. Acad Emerg Med. Feb 1996;3(2):99-100. [Medline].

  66. Snover SW, Bocchino V. Massive diltiazem overdose. Ann Emerg Med. Oct 1986;15(10):1221-4. [Medline].

  67. Spiller HA, Meyers A, Ziemba T, Riley M. Delayed onset of cardiac arrhythmias from sustained-release verapamil. Ann Emerg Med. Feb 1991;20(2):201-3. [Medline].

  68. Sporer KA, Manning JJ. Massive ingestion of sustained-release verapamil with a concretion and bowel infarction. Ann Emerg Med. Mar 1993;22(3):603-5. [Medline].

  69. Stone CK, May WA, Carroll R. Treatment of verapamil overdose with glucagon in dogs. Ann Emerg Med. Mar 1995;25(3):369-74. [Medline].

  70. Stone CK, Thomas SH, Koury SI, Low RB. Glucagon and phenylephrine combination vs glucagon alone in experimental verapamil overdose. Acad Emerg Med. Feb 1996;3(2):120-5. [Medline].

  71. Szekely LA, Thompson BT, Woolf A. Use of partial liquid ventilation to manage pulmonary complications of acute verapamil-sustained release poisoning. J Toxicol Clin Toxicol. 1999;37(4):475-9. [Medline].

  72. Thomas SH, Stone CK, Koury SI. Cardiac dysrhythmias in severe verapamil overdose: characterization with a canine model. Eur J Emerg Med. Mar 1996;3(1):9-13. [Medline].

  73. Tom PA, Morrow CT, Kelen GD. Delayed hypotension after overdose of sustained release verapamil. J Emerg Med. Sep-Oct 1994;12(5):621-5. [Medline].

  74. Tomaszewski C, McKinney P, Phillips S, Brent J, Kulig K. Prevention of toxicity from oral cocaine by activated charcoal in mice. Ann Emerg Med. Dec 1993;22(12):1804-6. [Medline].

  75. Tuncok Y, Apaydin S, Gelal A, Ates M, Guven H. The effects of 4-aminopyridine and Bay K 8644 on verapamil-induced cardiovascular toxicity in anesthetized rats. J Toxicol Clin Toxicol. 1998;36(4):301-7. [Medline].

  76. Tuncok Y, Apaydin S, Kalkan S, Ates M, Guven H. The effects of amrinone and glucagon on verapamil-induced cardiovascular toxicity in anaesthetized rats. Int J Exp Pathol. Oct 1996;77(5):207-12. [Medline].

  77. Verbrugge LB, van Wezel HB. Pathophysiology of verapamil overdose: new insights in the role of insulin. J Cardiothorac Vasc Anesth. Jun 2007;21(3):406-9. [Medline].

  78. Vogt S, Mehlig A, Hunziker P, Scholer A, Jung J, Gonzalez AB. Survival of severe amlodipine intoxication due to medical intensive care. Forensic Sci Int. Sep 12 2006;161(2-3):216-20. [Medline].

  79. Walter FG, Frye G, Mullen JT, Ekins BR, Khasigian PA. Amelioration of nifedipine poisoning associated with glucagon therapy. Ann Emerg Med. Jul 1993;22(7):1234-7. [Medline].

  80. Watling SM, Crain JL, Edwards TD, Stiller RA. Verapamil overdose: case report and review of the literature. Ann Pharmacother. Nov 1992;26(11):1373-8. [Medline].

  81. Wax PM. Intestinal infarction due to nifedipine overdose. J Toxicol Clin Toxicol. 1995;33(6):725-8. [Medline].

  82. Wells TG, Graham CJ, Moss MM, Kearns GL. Nifedipine poisoning in a child. Pediatrics. Jul 1990;86(1):91-4. [Medline].

  83. Wolf LR, Spadafora MP, Otten EJ. Use of amrinone and glucagon in a case of calcium channel blocker overdose. Ann Emerg Med. Jul 1993;22(7):1225-8. [Medline].

  84. Yuan TH, Kerns WP 2nd, Tomaszewski CA, Ford MD, Kline JA. Insulin-glucose as adjunctive therapy for severe calcium channel antagonist poisoning. J Toxicol Clin Toxicol. 1999;37(4):463-74. [Medline].

  85. Zaritsky AL, Horowitz M, Chernow B. Glucagon antagonism of calcium channel blocker-induced myocardial dysfunction. Crit Care Med. Mar 1988;16(3):246-51. [Medline].

Keywords

calcium channel blocker overdose, CCB overdose, CCB overdose symptoms, CCB overdose treatment, calcium channel blocker toxicity, calcium antagonists, verapamil, nifedipine, diltiazem, calcium channel blocker poisoning, calcium channel blocker exposure, angina, hypertension, arrhythmia, migraine prophylaxis

Contributor Information and Disclosures

Author

B Zane Horowitz, MD, FACMT, Professor, Department of Emergency Medicine, Oregon Health and Sciences University; Medical Director, Oregon Poison Center; Medical Director, Alaska Poison Control System
B Zane Horowitz, MD, FACMT is a member of the following medical societies: American Academy of Clinical Toxicology and American College of Medical Toxicology
Disclosure: Nothing to disclose.

Medical Editor

David C Lee, MD, Research Director, Department of Emergency Medicine, Associate Professor, North Shore University Hospital and New York University Medical School
David C Lee, MD is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, American College of Medical Toxicology, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

Pharmacy Editor

John T VanDeVoort, PharmD, Regional Director of Pharmacy, Sacred Heart & St. Joseph's Hospitals
John T VanDeVoort, PharmD is a member of the following medical societies: American Society of Health-System Pharmacists
Disclosure: Nothing to disclose.

Managing Editor

John G Benitez, MD, MPH, FACMT, FACPM, FAAEM, Associate Professor, Department of Medicine, Clinical Pharmacology Division, Vanderbilt University; Managing Director, Tennessee Poison Center
John G Benitez, MD, MPH, FACMT, FACPM, FAAEM is a member of the following medical societies: American Academy of Emergency Medicine, American College of Medical Toxicology, American College of Preventive Medicine, Society for Academic Emergency Medicine, Undersea and Hyperbaric Medical Society, and Wilderness Medical Society
Disclosure: Nothing to disclose.

CME Editor

John D Halamka, MD, MS, Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center
John D Halamka, MD, MS is a member of the following medical societies: American College of Emergency Physicians, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

Chief Editor

Asim Tarabar, MD, Assistant Professor, Director, Medical Toxicology, Department of Emergency Medicine, Yale University School of Medicine; Consulting Staff, Department of Emergency Medicine, Yale-New Haven Hospital
Disclosure: Nothing to disclose.

Further Reading

© 1994- by Medscape.
All Rights Reserved
(http://www.medscape.com/public/copyright)